Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 2Signs and Symptoms 1Multiple Myeloma 1Lymphoma 1Hematopoietic and Lymphoid System Neoplasm 1Hematopoietic and Lymphatic System Neoplasm 1Head and Neck Neoplasms 1Fatigue 1Breast Neoplasms 1Advanced Malignant Solid Neoplasm 1

Interventions

pembrolizumab 90Blood Specimen Collection 41Cyclophosphamide 37Bevacizumab 36Nivolumab 35Standard of Care 32Carboplatin 31Surveys and Questionnaires 29Paclitaxel 27atezolizumab 25Exercise 25Pemetrexed 24Gemcitabine 23Cisplatin 23Fluorouracil 22Radiotherapy 20Leucovorin 20Dexamethasone 20Docetaxel 19Oxaliplatin 18Rituximab 16Irinotecan 16Cetuximab 16dostarlimab 15Drug Therapy 15Doxorubicin 15Ipilimumab 14Biopsy 14130-nm albumin-bound paclitaxel 14fludarabine 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × Mindfulness-Based Stress Reduction × 1 year × Clear all
NCT07124481 2025-08-15

EarlyMind

Isala

Phase NA Not yet recruiting
208 enrolled
Tumor-Agnostic

Neoplasms

NCT01919853 2025-07-02

Treatment for Persistently Fatigued Cancer Survivors: A Randomized Controlled Trial With Biomarker Response

Indiana University

Phase NA Completed
107 enrolled

Fatigue, Neoplasms, Signs and Symptoms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡